Skip to main content
Equibles
IART logo

IART · Integra Lifesciences Holdings Corp · Metrics

Track IART — free

Use IART with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IART.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$12.02 -0.31 (-2.47%)
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$958.55M
Shares
77.77M
Volume · Oct 23 282.6K Avg daily vol (3M) 956.25K

IART metrics

99 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$12.33
Market cap
$958.55M

Price action

20 metrics
Price change (1W)
-8.9%
Price change (30D)
-23.1%
Price change (3M)
-33.6%
Price change (6M)
+19.4%
Price change (YTD)
-0.8%
Price change (1Y)
-20.3%
Trailing year
Price change (5Y)
-82.6%
52-week high
$19.85
52-week low
$8.90
Change from 52-week high
-37.9%
Change from 52-week low
+38.5%
Annualized volatility
64.5%
Annualized volatility (3M)
70.7%
Beta
1.8
RSI (14D)
35.3
Price vs SMA 50
-20.3%
Price vs SMA 200
-12.5%
Avg volume (3M)
956,241
Relative volume
1.5
Average dollar volume
$14.87M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
77.77M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.8×
reciprocal yield 121.7%
EV / EBITDA
8.4×
reciprocal yield 11.9%
EV / EBIT
20.7×
reciprocal yield 4.8%
P / sales
0.6×
reciprocal yield 178.9%
P / book
0.9
reciprocal yield 113.3%
FCF yield
2.8%
TTM · current market cap
Buyback yield
0.0%
P / FCF
35.7
reciprocal yield 2.8%
P / operating cash flow
10.8
reciprocal yield 9.3%
Earnings yield
-0.8%

Historical valuation

8 metrics
P / E historical average (3Y)
35.6×
reciprocal yield 2.8%
P / E historical average (5Y)
48.7×
reciprocal yield 2.1%
EV / revenue historical average (3Y)
1.3×
reciprocal yield 76.6%
EV / revenue historical average (5Y)
2.2×
reciprocal yield 45.1%
EV / EBIT historical average (3Y)
59.8×
reciprocal yield 1.7%
EV / EBIT historical average (5Y)
41.6×
reciprocal yield 2.4%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-21

Profitability

9 metrics
Gross margin
52.5%
Operating margin
4.0%
Trailing 12 months
Net margin
-0.4%
Gross profit (TTM)
$864.58M
Operating profit (TTM)
$65.56M
Net income (TTM)
−$7.24M
Trailing 12 months
Diluted EPS (TTM)
$-0.10
FCF margin
1.6%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$21.35
Gross profit per diluted share (TTM)
$11.20
Operating profit per diluted share (TTM)
$0.85
EBITDA per diluted share (TTM)
$1.98
Net income per diluted share (TTM)
$-0.10
Operating cash flow per diluted share (TTM)
$1.11
Free cash flow per diluted share (TTM)
$0.33
Capital expenditures per diluted share (TTM)
$0.77
R&D per diluted share (TTM)
$1.23
Stock compensation per diluted share (TTM)
$0.29
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+0.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.65B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1.9%
Year over year · more shares
Revenue CAGR (3Y)
+1.6%
Revenue CAGR (5Y)
+3.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-0.7%
Return on assets
-0.2%
Debt / equity
0.7
Current ratio
3.6
EBITDA (TTM)
$170.98M
Free cash flow (TTM)
$25.80M
Quick ratio
2.1
Interest coverage
0.7
Net debt / EBITDA
3.0
Return on invested capital
—
Trailing 12 months
Net cash
−$433.10M
Latest balance sheet
Cash & equivalents
$214.41M
Total assets
$3.56B
Total debt
$707.19M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$85.33M
Capital expenditures (TTM)
$59.52M
R&D (TTM)
$95.00M
SG&A (TTM)
$688.98M
Stock compensation (TTM)
$22.43M
R&D / revenue
5.8%
Stock compensation / revenue
1.4%

Ownership (13F)

9 metrics
13F filers
212
13F filer change QoQ
+10
Institutional ownership
94.3%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
26.7%
Private-fund adviser ownership
25.6%
Active holders' share change QoQ
-4.0%
Holder tenure
14.6
Price vs estimated holder cost
+1.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
25.7%

Short interest

3 metrics
Short interest
9.3%
Latest settlement · 7.5 days to cover
Days to cover
7.5d
Short-squeeze score
82 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 917520 CUSIP 457985208 13F (30d) 26 filings 26 filers Visit website Investor relations